SCHEMBL4855879

SCHEMBL4855879

O=C1Nc2ccccc2Nc2cc(-c3cn(C4CCCC4)c4cnccc34)ccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 8/20 0.53
ROCK2 O75116 7/20 0.53
IRAK4 Q9NWZ3 7/20 0.53
CDK2 P24941 5/20 0.53
CDC7 O00311 4/20 0.53
MAP4K4 O95819 4/20 0.53
CLK4 Q9HAZ1 4/20 0.53
PRKACA P17612 3/20 0.53
HIPK2 Q9H2X6 2/20 0.53
MKNK2 Q9HBH9 2/20 0.53
DYRK1A Q13627 5/20 0.47
CHEK1 O14757 7/20 0.44
KDR P35968 2/20 0.43
KCNH2 Q12809 3/20 0.41
PDPK1 O15530 2/20 0.40
PRKX P51817 1/20 0.40
TNK2 Q07912 1/20 0.40
FLT3 P36888 2/20 0.39
SLK Q9H2G2 2/20 0.39
CDK1 P06493 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4847606 0.88 GSK3B (0.53) GSK3BROCK2IRAK4CDK2CDC7
SCHEMBL4851836 0.78 CHEK1 (0.79) GSK3BROCK2IRAK4CDK2DYRK1A
SCHEMBL4849396 0.77 DYRK1A (0.60) GSK3BROCK2IRAK4CDK2CDC7
SCHEMBL4851580 0.77 CHEK1 (0.48) GSK3BROCK2IRAK4CDK2CDC7
SCHEMBL4854997 0.77 GSK3B (0.53) GSK3BROCK2IRAK4CDK2CDC7
SCHEMBL4857917 0.74 IRAK4 (0.51) GSK3BROCK2IRAK4CDK2CDC7
SCHEMBL4857059 0.74 ROCK2 (0.50) GSK3BROCK2IRAK4CDK2CDC7
SCHEMBL4857031 0.74 CHEK1 (0.54) GSK3BROCK2IRAK4CDK2CDC7
SCHEMBL4847854 0.73 CHEK1 (0.80) GSK3BROCK2IRAK4CDK2DYRK1A
SCHEMBL4857465 0.73 GSK3B (0.57) GSK3BROCK2IRAK4CDK2CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US claimed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 GSK3B 465/4885ROCK2 483/4885IRAK4 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.